Moexipril

Mechanism-of-action class: Angiotensin-converting Enzyme Inhibitors.

• Moexipril hydrochloride tablets are indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics.ICD-10: I10

• Moexipril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Do not co-administer aliskiren with moexipril hydrochloride tablets in patients with diabetes (see PRECAUTIONS, Drug Interactions ).contraindicated

DOSAGE AND ADMINISTRATION

WARNINGS

Moexipril hydrochloride tablets have been evaluated for safety in more than 2500 patients with hypertension; more than 250 of these patients were treated for approximately one year. The overall incidence of reported adverse events was only slightly greater in patients treated with moexipril hydrochloride tablets than patients treated with placebo. Reported adverse experiences were usually mild and transient, and there were no differences in adverse reaction rates related to gender, race, age, duration of therapy, or total daily dosage within the range of 3.75 mg to 60 mg. Discontinuation of therapy because of adverse experiences was required in 3.4% of patients treated with moexipril hydrochloride tablets and in 1.8% of patients treated with placebo. The most common reasons for discontinuation in patients treated with moexipril hydrochloride tablets were cough (0.7%) and dizziness (0.4%).

Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg. No data are available to suggest that physiological maneuvers (e.g., maneuvers to change the pH of the urine) would accelerate elimination of moexipril and its metabolites. The dialyzability of moexipril is not known. Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of moexipril overdose, but angiotensin II is essentially unavailable outside of research facilities. Because the hypotensive effect of moexipril is achieved through vasodilation and effective hypovolemia, it is reasonable to treat moexipril overdose by infusion of normal saline solution. In addition, renal function and serum potassium should be monitored.

• May 8, 2003ANDAANDA076204Teva
• Nov 30, 2006ANDAANDA077536Chartwell Rx
• Mar 30, 2010ANDAANDA090416Glenmark Pharms Ltd

1. 1Asthenia812%
2. 2Dyspnoea69.0%
3. 3Nausea57.5%
4. 4Blood Pressure Decreased46.0%
5. 5Cerebrovascular Accident46.0%
6. 6Cough46.0%
7. 7Dehydration46.0%
8. 8Diarrhoea46.0%
9. 9Drug Ineffective46.0%
10. 10Flushing46.0%
11. 11Headache46.0%
12. 12Hypertension46.0%
13. 13Malaise46.0%
14. 14Arthralgia34.5%
15. 15Blood Pressure Increased34.5%

The 10 most recently updated of 12 ClinicalTrials.gov registrations naming Moexipril as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
  Not yet recruiting · Phase 4 · Interventional · 64 enrolled · Baylor Research Institute
  NCT07547878updated 2026-05-08
• Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
  Not yet recruiting · Observational · 13,656 enrolled · First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
  NCT07262710updated 2025-12-04
• Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
  Recruiting · Observational · 180 enrolled · Beijing Friendship Hospital
  NCT05498675updated 2025-02-13
• Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions
  Completed · Phase 1 · Interventional · 60 enrolled · Teva Pharmaceuticals USA
  NCT00834067updated 2024-08-20
• Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions
  Completed · Phase 1 · Interventional · 60 enrolled · Teva Pharmaceuticals USA
  NCT00835042updated 2024-08-20
• Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
  Completed · Phase 4 · Interventional · 291 enrolled · University of Nebraska
  NCT01669434updated 2023-09-25
• ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
  Completed · Observational · 22,213 enrolled · University of Utah
  NCT04467931updated 2021-04-28
• ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients
  Terminated · Interventional · 59 enrolled · Duke University
  NCT01867047updated 2017-09-28
• A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions
  Completed · Phase 1 · Interventional · 48 enrolled · Paddock Laboratories, Inc.
  NCT00990301updated 2013-11-25
• A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions
  Completed · Phase 1 · Interventional · 60 enrolled · Paddock Laboratories, Inc.
  NCT00992862updated 2013-09-26

Frequently asked questions

How does Moexipril work?

Mechanism-of-action class: Angiotensin-converting Enzyme Inhibitors.

What is Moexipril used for?

According to FDA labeling, Moexipril carries indications including: Moexipril hydrochloride tablets are indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Moexipril?

Moexipril is classified as ACE inhibitors, plain, Angiotensin-converting Enzyme Inhibitors, Decreased Blood Pressure, Decreased Bradykinin Degradation, Decreased Intravascular Volume, Decreased Mineralocorticoid Secretion, Decreased Renal K+ Excretion, Increased Renal Na+ Excretion, Renal Arterial Vasodilation.

What are the contraindications for Moexipril?

Moexipril labeling lists contraindications including: Moexipril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. Do not co-administer aliskiren with moexipril hydrochloride tablets in patients with diabetes (see PRECAUTIONS, Drug Interactions ).. Always consult the full prescribing information and a clinician.